Chiusura precedente | 3,0000 |
Aperto | 3,0400 |
Denaro | 3,1200 x 800 |
Lettera | 3,3000 x 800 |
Min-Max giorno | 3,0300 - 3,3200 |
Intervallo di 52 settimane | 0,8000 - 8,2900 |
Volume | |
Media Volume | 318.809 |
Capitalizzazione | 207,216M |
Beta (5 anni mensile) | 0,34 |
Rapporto PE (ttm) | N/D |
EPS (ttm) | -3,6500 |
Prossima data utili | 06 nov 2023 - 10 nov 2023 |
Rendimento e dividendo (futuro) | N/D (N/D) |
Data ex dividendo | N/D |
Stima target 1A | 4,50 |
DURHAM, N.C., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing, today announced that Mark Singleton, senior vice president and chief financial officer, will participate in a fireside chat at the Cantor Global Healthcare Conference on Thursday, September 28, 2023, at 1:50 p.m. ET. A live audio webcast of the fireside chat will be available on the “Investors” section of the Company’s website at www.bioventus.com and will be availabl
DURHAM, N.C., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing, today announced that Tony Bihl, interim chief executive officer, will participate in a fireside chat at the Morgan Stanley Global Healthcare Conference on Wednesday, September 13, 2023, at 8:50 a.m. ET. A live audio webcast of the fireside chat will be available on the “Investors” section of the Company’s website at www.bioventus.com and will be available for replay o
DURHAM, N.C., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or "the Company"), a global leader in innovations for active healing, today reported financial results for the three and six months ended July 1, 2023. Q2 Financial Summary: Net Sales of $137.1 million, down $3.3 million, or 2.3%, year-over-year as reported (2.3% constant currency*), excluding revenues from divested assets, underlying organic sales decreased $0.5 million, or 0.3% year-over-yearNet Loss from